NLR demonstrated the best diagnostic value in WHO II IDH wild-type and IDH mutant gliomas (p-value < 0.0001; median 1.63 and 1.95, respectively), WHO III (p-value = 0.0019; median 1.76 and 2.13) and WHO IV gliomas (p-value 0.0177, median 2.78 and 3.18, respectively) were significantly different (Figure 5A). The gene discussed is IDH1; the disease is central nervous system cancer.